Article Text

Download PDFPDF

Letter
COVID-19 diagnosis in the emergency department: seeing the tree but losing the forest
Free
  1. Dimitra S Mouliou,
  2. Ioannis Pantazopoulos,
  3. Konstantinos Gourgoulianis
  1. Department of Respiratory Medicine, Faculty of Medicine, University of Thessaly, Larissa, Greece
  1. Correspondence to Ms Dimitra S Mouliou, Department of Respiratory Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece; demymoole{at}gmail.com

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Dear Editor,

We have read with the greatest interest the article by Reynard et al.1 They have compared rapid antigen tests with PCR, which they consider to be the only molecular method. However, lateral flow assays (LFAs) together with several other laboratory methods are performed for the ‘molecular’ diagnosis of SARS-CoV-2.2 Furthermore, since the appearance of rapid nucleic assays, the term ‘rapid test’ for antigen/antibody assays can lead to misunderstanding and should be avoided.

Moreover, it is impossible to compare substantially different methods, referring to PCR and rapid point-of-care tests. It is obvious that ‘PCR inhibitors’ would lead to higher Ct values and subsequent false-negative results.3 Also, while PCR assay results are accurate in high viral loads, the so-called Hook effect would lead to false-negative results in LFAs, thus trammelling the comparison of these assays.3

Current literature has revealed several reasons for false COVID-19 test results, among different assays.3 The authors have tried to rate the sensitivity of each test but instead of that, we believe that emergency physicians should identify potential reasons for false test results and, thus, prevent misdiagnosis. Retesting and alternative testing (alternative sample/target/test kit) is the key for COVID-19 management in ambiguous cases.

Finally, the authors propose mass-testing as a future direction. Although we agree, this is an epidemiological prospect, far away from the emergency department practice. It is also suggested that future studies should correlate infectivity with viral load, omitting that a positive test result indicates SARS-CoV-2 carriers and not patients. Furthermore, pre-existent immunity (previous infection or vaccination) could prevent a severe COVID-19 disease, despite the detected viral load.

Ethics statements

Patient consent for publication

Ethics approval

This study does not involve human participants.

References

Footnotes

  • Correction notice Since this letter was published online, the corresponding author title has been updated from Dr to Ms.

  • Contributors All authors have contributed equally and approved the final version of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles

  • PostScript
    Charles Reynard Joy A Allen Bethany Shinkins Graham Prestwich Johnathan Goves Kerrie Davies Richard Body